NSAIDs and cardiovascular disease: time to say no to diclofenac

Internal and Emergency Medicine

Volumn 11, Issue 1, 2016, Pages 1-2

  Ungprasert, Patompong ^a,b  

^a MAYO CLINIC   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DICLOFENAC; HUMANS;

EID: 84958120317     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-015-1295-4     Document Type: Article

References (14)

1. Curhan GC, Bullock AJ, Hankinson SE, Willett WC, Speizer FE, Stampfer MJ (2002) Frequency of use of acetaminophen, nonsteroidal anti-inflammatory drugs, and aspirin in US women. Pharmacoepidemiol Drug Saf 11:687–693
2. Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS (2000) Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 27:1876–1883
3. Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL (2015) Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis. Eur J Int Med 26:285–291
4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092–1102
5. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633–1644
6. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann P (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 20:1225–1236
7. Garcia-Poza P, De Abajo FJ, Gil MJ, Chacon A, Bryant V, Garcia-Rodriguez LA (2015) Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study. J Thromb Haemost 13:708–718
8. Chuang SY, Yu Y, Sheu WH, Tsai YT, Liu X, Hsiung CA, Tsai HJ (2015) Association of short-term use of nonsteroidal anti-inflammatory drugs with stroke in patients with hypertension. Stroke 46:996–1003
9. Lapi F, Piccinni C, Simonetti M, Levi M, Lora-Aprile P, Cricelli I, Cricelli C, Fanelli A (2015) Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study. Int Emerg Med. doi:10.1007/s11739-015-1288-3
10. Patrono C, Patrignani P, Carcia-Rodriguez L (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7–13
11. Aneja A, Farkouh ME (2008) Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edea? Ther Adv Cardiovasc Dis 2:53–66
12. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC (2005) Effects of specific COX-2 inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 68:2197–2207
13. Graff J, Skarke C, Klinkhardt U, Watzer B, Harder S, Seyberth H, Geisslinger G, Nusing RM (2007) Effect of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 12:2376–2385
14. Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL (2015) Non-steroidal anti-inflammatory drug and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatol (Oxf) 54:736–742